A B S T R A C T The influence of serum triiodothvronine (T3) and thyroxine (T4) concentrations on the release of prolactin in man was studied by determining the prolactin response to synthetic thyrotropin-releasing hormone (TRH) in hypothyroid and hyperthyroid patients before and after correction of their serum thyroid hormone abnormalities. The maximum increment in serum prolactin above the basal level (maximum A prolactin) was used as the index of response to TRH.
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In 12 patients with primary hypothyroidism, the maximum A prolactin in response to TRH fell from 100.5± 29.1 ng/ml (mean +SEM) before treatment to 36.1±6.0 ng/ml (P < 0.01) during the 4th Nk of treatment with 30 jug T3 + 120 jug T4 daily. The mean serum T3 level increased from 57±8 to 138+10 ngl100 nml! and the mean serum T4 level increased from 3.0±0.4 to 7.2±0. 4 Ag/lOO ml during this treatment. In eight normal subjects the maximum Aprolactin in response to TRH was not significantly different during the 4th wk of treatment with 30 Ag T3 + 120 /g T4 daily from the response before treatment. In 10 patients with hvperthyroidism, the maximum Aprolactin in response to TRH increased from 14 .2±2.9 ng/ml before treatment to 46.9±6.7 nig/ml (P < 0.001) during antithyroid treatment. The mean serum T3 level fell from 313±47 to 90±8 ng/100 ml, and the mean serum T4 level fell from 20.8±2.5 to 6.8+ 0.6 Ig/100 ml during this treatment.
These results show that changes from normal serum levels of T3 Analyses. Serum T3 (7), TSH (8) , and prolactin (9) were measured by immunoassay. The standard used in the prolactin immunoassay was a serum rich in prolactin from a patient with a prolactin-secreting pituitary tumor. This serum was standardized against two other sera that had been bioassayed (9) and against highly purified human prolactin (10) . The maximum increment in serum prolactin above the basal level (maximum Aprolactin) after TRH administration was used as the index of prolactin response to TRH. Serum T4 was measured by competitive protein binding (11) . Normal values for these assays in our laboratories are as follows: serum Ts, 70-150 ng/100 ml; serum T4, 5-11 Mug!100 ml; serum TSH, <2-8,MU/ml; and serum prolactin, <2-25 ng/ml. All samples for these assays from any one subject were analyzed in the same assay run. The paired t test (12) and the Wilcoxon signed rank test (13) were used to assess statistical significance. When not stated otherwise in the Results section, the paired t test was used. The correlation coefficient (14) was used to determine the degree of correlation between thyroid hormone levels and prolactin response.
RESULTS
Hypothyroid patients. Fig. 1 The fall in the prolactin response to TRH after thyroid hormone replacement was examined in greater detail by comparing the maximum Aprolactin of each hypothyroid patient before and during thyroid hormone replacement, as shown in Fig. 2 . The maximum Aprolactin was lowered by thyroid hormone replacement in 11 of the 12 patients, and the mean maximum Aprolactin fell from 100.5±29.1 ng/ml to 36.1±6.0 ng/ml. Because of the skewness of the individual changes in maximum Aprolactin, as determined by considerable discrepancy between the mean and median changes in the maximum Aprolactin values (mean change, 64.4 ng/ml; median change, 14.1 ng/ml), the statistical sig-nificance of the change in maximum Aprolactin was evaluated with the Wilcoxon signed rank test. The fall in maximum Aprolactin after thyroid hormone replacement was statistically significant, P < 0.01. Fig. 2 also shows that at the time of the TRH test, before thyroid treatment, the mean serum Ts and T4 levels were both in the hypothyroid ranges, and that at the time of the TRH test, during thyroid hormone treatment, the mean serum T3 and T4 levels were both in the normal ranges. No significant correlations existed between the pretreatment serum T3 or T4 levels and the pretreatmenit maximum Aprolactin responses.
Euthyroid subjects. Fig. 3 shows the mean serum prolactin response of eight normal, euthyroid subjects to the i.v. injection of 400 ,ug TRH before treatment and during the 4th wk of treatment with 30 iug T3 + 120 jug T4 once daily. The basal prolactin levels were 12.5±1.5 ng/ml before and 12.1±+1.2 ng/ml during this thyroid hormone treatment. The peak prolactin levels after TRH were 41.9+4.1 ng/ml before and 39.5±3.8 ug/ml durinig treatment. The change in the mean pre-TRH prolactin level was not significant. Fig. 4 shows the maximum Aprolactin for each subject before and during thyroid hormone treatment. The maximum Aprolactin of two subjects fell by 62 and 31%1o respectively, but the imaximum Aprolactin of the other subjects changed by less than 9% each. The mean maximum Aprolactin levels before and during treatment were not significantly different. Serum T3 levels rose a small but signiificanit (P < 0.05) amount during thyroid hormolne treatmenit, but serum T4 levels did not change significantly (Fig. 4) .
Hyperthyroid paticnts. Fig. 5 Fig. 6 . The maximum Aprolactin was higher during antithyroid treatment in 9 of the 10 subjects. The mean maximum Aprolactin rose from 14.2±2.9 ng/ml before antithyroid treatment to 46.9+6.7 ng/ml during treatment. This rise in maximum Aprolactin was highly significant statistically, P < 0.001. Fig. 6 also shows that at the time of the TRH test before antithyroid treatment, the mean serum T3 and T4 levels were both in the hyperthyroid ranges and that at the time of the TRH test during antithyroid treatment, the mean serum T3 and T4 levels were both in the normal ranges.
The changes in maximum Aprolactin and in serum T3 and T4 levels were similar in subjects treated with methimazole and in those treated with radioactive iodide.
A negative correlation of borderline significance (r = -0.61, P < 0.05) was found between the pretreatment serum T3 levels and the pretreatment prolactin responses to TRH.
DISCUSSION
The data presented here demonstrate that the similarity between the regulation of TSH secretion and prolactin secretion includes not only stimulation of both hormones by TRH but also inhibition of the TRH-induced stimulation of both by thyroid hormones. The prolactin response to TRH is increased when serum T3 and T4 levels are below the normal ranges, as demonstrated by the significant fall in prolactin response when subjects with primary hypothyroidism were retested after they had been made euthyroid (Fig. 2) . The possibility that part of this fall was due to the production of hyperthyroidism by the replacement thyroid medication was excluded by demonstrating that the prolactin response to TRH was not significantly lowered by treating normal, euthyroid subjects with the same dose of thyroid hormones as the hypothyroid subjects were treated (Fig.  4) . The prolactin response to TRH is decreased when serum T3 and T4 levels are above the normal ranges, as demonstrated by the significant increase in prolactin response when subjects with hyperthyroidism were retested after they had been made euthyroid (Fig. 6) . Foley, Jacobs, Hoffman, Daughday, and Blizzard reported that in eight of nine children with secondary hypothyroidism, all but one case due to presumptive deficiency of endogenous TRH secretion, the prolactin reThyroid Hormone Inhibition of Prolactin Response to TRH 60r sponse to exogenous TRH was also diminished by treatnment with replacement thyroid medication (15) . Bowers, Friesen, Huang, Guyda, and( Folkers noted a similar effect in one patient with hypothyroidism secondary to a pituitary tumor and in another patienit with primary hypotlhyroidism (1) . With the exception of this last patient, changes in the prolactin response to TRH after changes in serum T3 and T4 levels have not been reported previously in patients with primary hypothyroidism and have not been reported at all in patients with hyperthyroidism or in normal subjects. Bowers et al. (1) found no difference between the prolactin responses in a group of 14 patients with primary hypothyroidism and those in a separate control group of 12 subjects. but responses in a group of 6 patients with hyperthyroidism were lower than those in the control group. The lack of difference between the prolactin responses of the p)atients with primary hypothyroidism and the control subjects was probably due to a combination of the wide variability in individual prolactin responses to TRH (6) anid the use of a separate group of control subjects, ratlher than the use of each patient with primary hypothyroidisnm as his own control after thyroid replacement.
These results also shoNv that the inhibition of l)rolactin secretion y serum T3 and T4 levels differs from the inhibition of TSH by T3 and T4 in at least two respects. First, basal prolactin levels are not generally elevated in primary hypothyroidism, as are TSH levels (8) . Second, TRH-stimulated prolactin release is not quite so sensitive as TSH release to inhibition by elevated levels of serum T3 and T4 ; TRH-inducedl prolactin release is not significantly affected by the treatment of normal subjects with 30 jug T3 + 120 Ag T4 daily for 3-4 wk (Fig. 4) , whereas TRH-induced TSH release is reduced by 95% by treatment of normal subjects in this way (4) .
The data presented here do not elucidate the meclhanisms by which TRH stimulates prolactin release and by Nhich thyroid hormones inhibit this effect. It is tempting to make an analogy to the TRH-TSH-T3, T4 axis and to assume that TRH directly stimulates the pituitary to secrete prolactin and that T3 and T4 directlv inhibit this pituitary secretion. The results presented here, however, are not evidence for or against this hypothesis or for or against the possibility that anl intermediary hypothalamic factor, a prolactin-releasing hormone, is involved. The data on TRH-induced prolactin release in subjects with hypothyroidism due to pituitary (1, 16) or hvpothalamic (15, 17) disease likewise do not help to elucidate the mechanisms by which TRH stimulates prolactin release and thyroid hormones inhibit this stimulus.
An intermediary role for TSH in TRH-iniduced prolactin release does appear to be excluded, however, since normal subjects treated with 30 yg T3 + 120 jg T4 had a normal prolactin response to TRH (Fig. 4) WVe conclu(le thalt changes from normal seruml levels of T3 and T4 are associated with chalnges in prolactin responses to TRH; subnormal serum levels of T3 and T4 increase TRH-induced prolactin release, whereas substantially higher than nornmal serum levels of T3 and T4 inhlibit this release. The mechanisms by whichl these effects occuir are as yet unknown.
